- Page 1 and 2:
ANNUAL REPORT 2012
- Page 3 and 4:
9. MAJOR SHAREHOLDERS 103 9.1. OVER
- Page 5 and 6:
There can be no assurance that TiGe
- Page 7 and 8:
educing their ultimate value to the
- Page 9 and 10:
eimbursement in certain instances s
- Page 11 and 12:
or the relevant manufacturing proce
- Page 13 and 14:
In recent years, it expanded its op
- Page 15 and 16:
making this change may be costly an
- Page 17 and 18:
TiGenix’s development stage produ
- Page 19 and 20:
qualified employees and consultants
- Page 21 and 22:
1. Introduction Annual report 2012
- Page 23 and 24:
2. Persons Responsible for the Cont
- Page 25 and 26:
4. Selected Financial Information Y
- Page 27 and 28:
5.3. ORGANISATIONAL STRUCTURE TiGen
- Page 29 and 30: Date Transaction Number and class o
- Page 31 and 32: Date Transaction Number and class o
- Page 33 and 34: (12) The shares were subscribed to
- Page 35 and 36: 5.5. DESCRIPTION OF RIGHTS AND BENE
- Page 37 and 38: Formalities to attend the sharehold
- Page 39 and 40: amendments to the Articles of Assoc
- Page 41 and 42: the existing shareholders have a pr
- Page 43 and 44: Issue date Term Number of warrants
- Page 45 and 46: 6. Business Overview Most of the in
- Page 47 and 48: 6.2. COMPETITIVE STRENGTHS The Comp
- Page 49 and 50: 6.3. IMPORTANT EVENTS IN THE DEVELO
- Page 51 and 52: 6.3.5. Funding history Since its in
- Page 53 and 54: non-weight bearing area of the join
- Page 55 and 56: 6.4.5. Commercial launch ChondroCel
- Page 57 and 58: und Behandlungsmethode”) in sever
- Page 59 and 60: Therapeutics (product Hyalograft C)
- Page 61 and 62: Different routes of administration
- Page 63 and 64: Clinical development In January 201
- Page 65 and 66: evenues from this pipeline within t
- Page 67 and 68: that the average cost of treatment
- Page 69 and 70: TiGenix has obtained cGMP status fo
- Page 71 and 72: Biologics for treatment of Rheumato
- Page 73 and 74: of the patents and patent applicati
- Page 75 and 76: - “Marker genes for use in the id
- Page 77 and 78: manufacturing process and therapeut
- Page 79: Invalidation of US patent US6777231
- Page 83 and 84: 7.2.3. Independent directors As to
- Page 85 and 86: 7.2.4. Composition of the Board of
- Page 87 and 88: of Ravago NV, Vanbreda Risk & Benef
- Page 89 and 90: Litigation statement concerning the
- Page 91 and 92: As proof of the independence and an
- Page 93 and 94: for their healthcare and biotechnol
- Page 95 and 96: 7.5. SCIENTIFIC ADVISORY BOARD AND
- Page 97 and 98: As of the date of publication of th
- Page 99 and 100: (rounded down to the nearest intege
- Page 101 and 102: usiness at customary market conditi
- Page 103 and 104: 9. Major Shareholders 9.1. OVERVIEW
- Page 105 and 106: 10. Financial Statements : General
- Page 107 and 108: 11. Consolidated Financial Statemen
- Page 109 and 110: 11.3. CONSOLIDATED STATEMENT OF CAS
- Page 111 and 112: The consolidated financial statemen
- Page 113 and 114: 11.5.2.2. Basis of consolidation Th
- Page 115 and 116: are provided and costs are incurred
- Page 117 and 118: of interest on the remaining balanc
- Page 119 and 120: Deferred tax assets and liabilities
- Page 121 and 122: - Partnering of Cx601 (i.e. finding
- Page 123 and 124: The Group is mainly exposed to the
- Page 125 and 126: fiscal year 2010, reference is made
- Page 127 and 128: Sales and marketing expenses Years
- Page 129 and 130: The number of employees in the R&D
- Page 131 and 132:
Analysis of profit/(loss) for the p
- Page 133 and 134:
(8) Disposal group held for sale Th
- Page 135 and 136:
(10) Property, plant and equipment
- Page 137 and 138:
The decrease of stock in 2012 compa
- Page 139 and 140:
dividends will be based upon the Co
- Page 141 and 142:
alance. As a consequence, the Compa
- Page 143 and 144:
(23) Other current liabilities The
- Page 145 and 146:
TiGenix SAU - Stock options Prior t
- Page 147 and 148:
(25) Business combination Descripti
- Page 149 and 150:
(26) Related party transactions Tra
- Page 151 and 152:
(28) Commitments and contingencies
- Page 153 and 154:
(30) Consolidation scope Name Subsi
- Page 155 and 156:
We believe that the audit evidence
- Page 157 and 158:
assets and liabilities, its financi
- Page 159 and 160:
the results of its operations and c
- Page 161 and 162:
12.2. STATUTORY BALANCE SHEET 2010-
- Page 163 and 164:
The value of receivables is reduced
- Page 165 and 166:
13. Annual Report of the Board of D
- Page 167 and 168:
2013. The facility will provide the
- Page 169 and 170:
year ended December 31, 2011, and T
- Page 171 and 172:
Operating result (EBIT) and net res
- Page 173 and 174:
Statement of financial position The
- Page 175 and 176:
- The total personnel costs of EUR
- Page 177 and 178:
- TiGenix may fail in successfully
- Page 179 and 180:
continue as a going concern and to
- Page 181 and 182:
Functioning of the Board of Directo
- Page 183 and 184:
The nomination and remuneration com
- Page 185 and 186:
Apart from the above remuneration f
- Page 187 and 188:
Shares and warrants held by indepen
- Page 189 and 190:
- Long-term incentive plan : warran
- Page 191 and 192:
Shares and warrants held by executi
- Page 193 and 194:
- identifying and implementing busi
- Page 195 and 196:
actual bonus equal to 78 % of her p
- Page 197 and 198:
was reduced to a half-time role com
- Page 199 and 200:
14. Business and Financial Update a
- Page 201 and 202:
Financial results for the full year
- Page 203 and 204:
15. Available Documents The Company
- Page 205 and 206:
Title Country Application number Ce
- Page 207 and 208:
Title Country Application number Is
- Page 209 and 210:
Country Trademark Classes USA CELLE